FIGURE

Fig. 4

ID

ZDB-FIG-240605-72

Publication

Ye et al., 2022 - c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

Combined treatment with flavopiridol and imatinib had a better response in Tg(hsp70:p210BCR/ABL1);c-mybhyper. (A–H) WISH of lcp1 expression in the drug-treated larvae at 4.5 dpf. After heat shock treatment, 2.5 dpf Tg(hsp70:p210BCR/ABL1) and Tg(hsp70:p210BCR/ABL1);c-mybhyper were treated for 48 h with 1‰ DMSO control, 0.1 μmol/L flavopiridol, 80 μmol/L imatinib, or 0.1 μmol/L flavopiridol combined with 80 μmol/L imatinib. (I), Quantification of numbers of 4.5 dpf lcp1+ cells in CHT (Tg(hsp70:p210BCR/ABL1) DMSO, n = 30; Tg(hsp70:p210BCR/ABL1) imatinib, n = 29; Tg(hsp70:p210BCR/ABL1) flavopiridol, n = 30; Tg(hsp70:p210BCR/ABL1) flavopiridol+imatinib, n = 29; Tg(hsp70:p210BCR/ABL1);c-mybhyper DMSO, n = 30; Tg(hsp70:p210BCR/ABL1);c-mybhyper imatinib, n = 31; Tg(hsp70:p210BCR/ABL1);c-mybhyper flavopiridol, n = 30; Tg(hsp70:p210BCR/ABL1);c-mybhyper flavopiridol+imatinib, n = 27). Scale bar, 100 μm; applies to panels (A–H).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Animal Model Exp Med